Key result
Peripheral oedema during rosiglitazone treatment was associated with a 5% decline in VO2peak-FFM and increased end-diastolic volume.
Why the study?
Does the development of peripheral edema during rosiglitazone treatment affect cardiac structure, function, and peak oxygen consumption in treated patients?
RCT (n=74)
Does the development of peripheral edema during rosiglitazone treatment affect cardiac structure, function, and peak oxygen consumption in treated patients?
Peripheral edema caused by rosiglitazone appears to be driven by volume expansion rather than adverse effects on intrinsic cardiac function.
Answers are grounded in this paper and cite their sources.
Associated oedema signals volume expansion with reduced VO2peak; hypothesis-generating for TZD monitoring without practice change.
BACKGROUND: Thiazolidinediones cause peripheral oedema, the aetiology of which remains poorly understood. METHODS: In a sub-study of a 6-month trial comparing rosiglitazone (Rsg) versus placebo, we compared those with versus without oedema among the 74 subjects treated with Rsg with respect to peak oxygen consumption indexed to fat-free mass (VO(2peak-FFM) ), cardiac MRI and markers of plasma volume expansion. RESULTS: Almost half (49%) of the Rsg-treated patients developed oedema. Baseline VO(2peak-FFM) was not different between those with versus without oedema (25.8 versus 28.2 ml/kg/min; p = 0.22) and declined 5% in the oedema group (Δ -1.3 ml/min/kg; p = 0.005) with no change in those without oedema. Stroke volume increased in both groups (Δ 8.7 and 8.8 ml; p < 0.001 for each); end-diastolic volume increased only in those with oedema (+13.1 ml; p = 0.001). No other cardiac function changes were observed. In both groups, weight increased (3.6 and 2.2 kg) and haematocrit decreased (-3.2% and -2.1%; p < 0.001 for each). In those with oedema, albumin decreased (-0.2 g/dl) and brain natriuretic peptide increased (11.9 pg/ml; p < 0.03 for each). CONCLUSIONS: Oedema was associated with a small decline in VO(2peak FFM), no adverse effects on cardiac function, and changes in selected measures suggesting that volume expansion underpins Rsg oedema.
No takes yet. Share an insight, caveat, or question.
Narang et al. (2011) conducted an RCT in Patients treated with rosiglitazone (n=74). Peripheral oedema vs. No peripheral oedema was evaluated on Change in peak oxygen consumption indexed to fat-free mass (VO2peak-FFM) (p=0.005). Peripheral oedema during rosiglitazone treatment was associated with a 5% decline in VO2peak-FFM and increased end-diastolic volume.
Synapse has enriched 10 related papers. Consider them for comparative context: